Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial

被引：0
|
作者：
Kappos, Ludwig [1 ]
Bar-Or, Amit [2 ]
Cree, Bruce [3 ]
Fox, Robert [4 ]
Giovannoni, Gavin [5 ]
Gold, Ralf [6 ]
Vermersch, Patrick [7 ]
Lam, Elaine [8 ]
Pohlmann, Harold [9 ]
Zhang-Auberson, Lixin [9 ]
Dandekar, Atul [9 ]
Wallstroem, Erik [9 ]
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] McGill Univ, Montreal Neurol Inst & Hosp, Neuroimmunol Unit, Montreal, PQ, Canada
[3] Univ Calif San Francisco, Multiple Sclerosis Ctr, San Francisco, CA 94143 USA
[4] Cleveland Clin, Neurol Inst, Mellen Ctr Treatment & Res Multiple Sclerosis, Cleveland, OH 44106 USA
[5] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England
[6] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[7] Univ Lille Nord France, Lille, France
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
来源：
NEUROLOGY | 2013年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P07126
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
    Kappos, L.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Lam, E.
    Pohlmann, H.
    Zhang-Auberson, L.
    Dandekar, A.
    Wallstrom, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 927 - 928
  • [2] Baseline Subgroup Characteristics of EXPAND: A Phase 3 Study of Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis
    Kappos, Ludwig
    Bar-Or, Amit
    Cree, Bruce
    Fox, Robert
    Giovannoni, Gavin
    Gold, Ralf
    Vermersch, Patrick
    Bhasin, Priya
    Arnould, Sophie
    Sidorenko, Tatiana
    Wallstroem, Erik
    [J]. NEUROLOGY, 2016, 86
  • [3] Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis (SPMS): baseline characteristics of the EXPAND study population
    Kappos, L.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Bhasin, P.
    Arnould, S.
    Sidorenko, T.
    Wallstroem, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 317 - 318
  • [4] Neurostatus e-Scoring (NESC): first experience in a phase 3 clinical trial with siponimod (BAF312) in secondary progressive multiple sclerosis (EXPAND)
    D'Souza, M.
    John, R.
    Andelova, M.
    Lorscheider, J.
    Rust, H.
    Gysin, S.
    Hunter, B.
    Wallstroem, E.
    Schnyder, F.
    Kappos, L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 21 - 22
  • [5] Basic immunological profile changes with BAF312 (siponimod) treatment in secondary progressive multiple sclerosis patients
    Mao-Draayer, Y.
    Wu, Q.
    Wang, Q.
    Dowling, C.
    Lundy, S.
    Fox, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 1015 - 1015
  • [6] Siponimod (BAF312): General Characteristics and Clinical Implications of Pharmacogenomic Dosage in the Treatment of Active Secondary Progressive Multiple Sclerosis
    Calfunao, Susan
    Carrasco, Matias
    Gutierrez, Carolina
    Cerpa, Leslie
    Varela, Nelson
    Quinones, Luis
    [J]. REVISTA MEDICA DE CHILE, 2023, 151 (10) : 1375 - 1384
  • [7] Basic immunological profile changes of secondary progressive multiple sclerosis patients treated with BAF312 (SIPONIMOD)
    Mao-Draayer, Y.
    Wu, Q.
    Wang, Q.
    Dowling, C.
    Lundy, S.
    Fox, D.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 783 - 783
  • [8] Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
    Gentile, Antonietta
    Musella, Alessandra
    Bullitta, Silvia
    Fresegna, Diego
    De Vito, Francesca
    Fantozzi, Roberta
    Piras, Eleonora
    Gargano, Francesca
    Borsellino, Giovanna
    Battistini, Luca
    Schubart, Anna
    Mandolesi, Georgia
    Centonze, Diego
    [J]. JOURNAL OF NEUROINFLAMMATION, 2016, 13
  • [9] Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
    Antonietta Gentile
    Alessandra Musella
    Silvia Bullitta
    Diego Fresegna
    Francesca De Vito
    Roberta Fantozzi
    Eleonora Piras
    Francesca Gargano
    Giovanna Borsellino
    Luca Battistini
    Anna Schubart
    Georgia Mandolesi
    Diego Centonze
    [J]. Journal of Neuroinflammation, 13
  • [10] Effects of Siponimod (BAF312) on Inflammation-Driven Synaptopathy in Experimental Multiple Sclerosis
    Gentile, Antonietta
    Musella, Alessandra
    Bullitta, Silvia
    Fresegna, Diego
    De Vito, Francesca
    Piras, Eleonora
    Gargano, Francesca
    Borsellino, Giovanna
    Battistini, Luca
    Mandolesi, Georgia
    Schubart, Anna
    Centonze, Diego
    [J]. NEUROLOGY, 2016, 86
12345